Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
Devicecobas EGFR Mutation Test v2
Generic Namesomatic gene mutation detection system
Applicant
ROCHE
4300 hacienda drive
po box 9002
pleasanton, CA 94588
PMA NumberP120019
Supplement NumberS031
Date Received04/30/2020
Decision Date10/27/2020
Product Code OWD 
Advisory Committee Pathology
Supplement Typenormal 180 day track
Supplement Reason labeling change - indications/instructions/shelf life/tradename
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for cobas® EGFR Mutation Test v2 label expansion to obtain companion diagnostic group labeling claim for EGFR Tyrosine Kinase Inhibitors (TKI) for specific EGFR mutations detected by the test.
-
-